Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX® 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France

NCT03746860 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT03746860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03746860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX® 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France
Lead sponsor
ALK-Abelló A/S
Phase
Observational
Overall status
Completed
Start date
May 9, 2018
Completion date
September 29, 2020
Enrollment
1,508 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic asthma due to dermatophagoides farinae, allergic asthma due to dermatophagoides pteronyssinus, allergic rhinitis due to house dust mite